Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...
If approved, crovalimab would be the first PNH drug that could be given by subcutaneous injection once a month outside a supervised healthcare setting, setting up a challenge to AstraZeneca's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback